Trial Profile
Pemetrexed +/- oxaliplatin as second-line therapy in patients with stage IV non-squamous non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Feb 2014
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary) ; Oxaliplatin
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 19 Feb 2014 New trial record